Abstract
Electronic cigarette (e-cigarette) use has had an exponential increase in popularity since the product was released to the public. Currently, there is a lack of human studies that assess different biomarker levels. This pilot study attempts to link e-cigarette and other tobacco product usage with clinical respiratory symptoms and immunoglobulin response. Subjects completed surveys in order to collect self-reported data on tobacco product flavor preferences. Along with this, plasma samples were collected to test for immunoglobulin G (IgG) and E (IgE) levels. Our pilot study’s cohort had a 47.9% flavor preference towards fruit flavors and a 63.1% preference to more sweet flavors. E-cigarette and traditional cigarette smokers were the two subject groups to report the most clinical symptoms. E-cigarette users also had a significant increase in plasma IgE levels compared to non-tobacco users 1, and dual users had a significant increase in plasma IgG compared to non-tobacco users 2, cigarette smokers, and waterpipe smokers. Our pilot study showed that users have a preference toward fruit and more sweet flavors and that e-cigarette and dual use resulted in an augmented systemic immune response.
Highlights
Toxicity from e-cigarette exposure has been observed in acellular, cellular, and human models
There was no significant change in plasma levels of immunoglobulin G (IgG) in e-cigarette users compared to non-tobacco users 1 (Figure 2B)
Our pilot study showed a significant elevation in levels in e-cigarette users compared to non-tobacco users 1, and e-cigarette product of allergic in e-cigarette users compared to non-tobacco userstraditional
Summary
Toxicity from e-cigarette exposure has been observed in acellular, cellular, and human models. E-cigarette vapors have been shown to generate acellular reactive oxygen species (ROS), and exposure to e-cigarette vapors results in an increased generation of ROS by small airway epithelial cells, which poses a potential for lung injury [1]. E-cigarettes use is perceived to be safer than traditional cigarette smoking as there are fewer carcinogens, but concerns regarding pulmonary and cardiovascular diseases remain [4]. Short-term e-cigarette use was found to have immediate adverse effects on pulmonary function, with an increase in lung impedance and peripheral airway flow resistance and a decrease in fractional exhaled nitric oxide [5]. Cardiovascular risks of e-cigarette use are found to be lower than the risks associated with traditional cigarette smoking, but they may pose a great risk to individuals with a predisposition to cardiovascular disease [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International journal of environmental research and public health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
